Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial

被引:0
|
作者
Wen, Xiaoyu [1 ]
Kong, Fei [1 ]
Wen, Xiaofeng [2 ]
Wang, Xiaozhong [3 ]
Lin, Shide [4 ]
Wu, Guicheng [5 ]
Wang, Li [6 ]
Xing, Huichun [7 ]
Yan, Xuebing [8 ]
Zheng, Sujun [9 ]
Ning, Qin [10 ]
Wang, Zheng [11 ]
Zhang, Liaoyun [12 ]
Li, Jianmei [13 ]
Tong, Zhaowei [14 ]
Su, Minghua [15 ]
Tong, Lixin [16 ]
Huang, Chengyu [17 ]
Jia, Ji-Dong [18 ]
Xin, Yongning [19 ]
Zhu, Qingjing [20 ]
Wang, Jing [21 ]
Zhang, Yuexin [22 ]
Li, Guangming [23 ]
Niu, Junqi [1 ]
机构
[1] First Hosp Jilin Univ, Hepatol, Changchun, Peoples R China
[2] Liuzhou Peoples Hosp, Liuzhou, Peoples R China
[3] Xinjiang Uygur Autonomous Reg Tradit Chinese Med, Tibetan, Peoples R China
[4] Zunyi Med Coll, Affiliated Hosp, Zunyi, Guizhou, Peoples R China
[5] Chongqing Three Gorges Cent Hosp, Chongqing, Peoples R China
[6] Chengdu Publ Clin Hlth & Med Ctr, Chengdu, Peoples R China
[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China
[8] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China
[10] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[11] Fifth Hosp Wuxi, Wuxi, Jiangsu, Peoples R China
[12] Shanxi Med Univ, Hosp 1, Jinzhong, Peoples R China
[13] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[14] Huzhou City Cent Hosp, Huzhou, Peoples R China
[15] Guangxi Med Univ, Hosp 1, Nanning, Peoples R China
[16] Hebei Med Univ, Hosp 1, Shijiazhuang, Hebei, Peoples R China
[17] Chongqing Publ Clin Hlth & Med Ctr, Chongqing, Peoples R China
[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[19] Qingdao City Cent Hosp, Qingdao, Peoples R China
[20] Jinyintan Hosp Wuhan, Wuhan, Peoples R China
[21] Southwest Med Univ, Tradit Chinese Med Hosp, Luzhou, Peoples R China
[22] Xinjiang Med Univ, Hosp 1, Urumqi, Peoples R China
[23] Zhengzhou Sixth Peoples Hosp, Zhengzhou, Peoples R China
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
THU391
引用
收藏
页码:S330 / S330
页数:1
相关论文
共 50 条
  • [41] A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 8 AND 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: OPTIMIST-1
    Kwo, P.
    Gitlin, N.
    Nahass, R.
    Bernstein, D.
    Rojter, S.
    Schiff, E.
    Davis, M.
    Ruane, P. J.
    Younes, Z.
    Kalmeijer, R.
    Peeters, M.
    Lenz, O.
    Fevery, B.
    De La Rosa, G.
    Scott, J.
    Sinha, R.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S270 - S270
  • [42] Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants
    Wu, Jing
    Giessmann, Thomas
    Lang, Benjamin
    Elgadi, Mabrouk
    Huang, Fenglei
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2016, 68 (04) : 459 - 466
  • [43] SUSTAINED VIRAL RESPONSE (SVR) RATES IN GENOTYPE 1 TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) INFECTION TREATED WITH VANIPREVIR (MK-7009), A NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
    Manns, Michael P.
    Gane, Edward J.
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht D.
    Yeh, Chau-Ting
    Marcellin, Patrick
    Wiedmann, Richard T.
    Hwang, Peggy
    Barnard, Richard J.
    Lee, Andrew W.
    HEPATOLOGY, 2010, 52 (04) : 361A - 361A
  • [44] EARLY VIRAL RESPONSE (EVR) RATES IN TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION TREATED WITH MK-7009, A NOVEL NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
    Manns, Michael P.
    Gane, Edward J.
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht D.
    Yeh, Chau-Ting
    Marcellin, Patrick
    Wiedmann, Richard T.
    Hwang, Peggy
    Barnard, Richard J.
    Quirk, Erin
    Kartsonis, Nicholas A.
    Lee, Andrew W.
    HEPATOLOGY, 2009, 50 (04) : 332A - 333A
  • [45] Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study
    Forestier, Nicole
    Larrey, Dominique
    Guyader, Dominique
    Marcellin, Patrick
    Rouzier, Regine
    Patat, Alain
    Smith, Patrick
    Bradford, Williamson
    Porter, Steven
    Blatt, Lawrence
    Seiwert, Scott D.
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2011, 54 (06) : 1130 - 1136
  • [46] Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
    Mizokami, Masashi
    Yokosuka, Osamu
    Takehara, Tetsuo
    Sakamoto, Naoya
    Korenaga, Masaaki
    Mochizuki, Hitoshi
    Nakane, Kunio
    Enomoto, Hirayuki
    Ikeda, Fusao
    Yanase, Mikio
    Toyoda, Hidenori
    Genda, Takuya
    Umemura, Takeji
    Yatsuhashi, Hiroshi
    Ide, Tatsuya
    Toda, Nobuo
    Nirei, Kazushige
    Ueno, Yoshiyuki
    Nishigaki, Yoichi
    Betular, Juan
    Gao, Bing
    Ishizaki, Akinobu
    Omote, Masa
    Mo, Hongmei
    Garrison, Kim
    Pang, Phillip S.
    Knox, Steven J.
    Symonds, William T.
    McHutchison, John G.
    Izumi, Namiki
    Omata, Masao
    LANCET INFECTIOUS DISEASES, 2015, 15 (06): : 645 - 653
  • [47] A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2
    Lawitz, E.
    Matusow, G.
    DeJesus, E.
    Yoshida, E.
    Felizarta, F.
    Ghalib, R.
    Godofsky, E.
    Herring, R.
    Poleynard, G.
    Sheikh, A.
    Tobias, H.
    Kugelmas, M.
    Kalmeijer, R.
    Peeters, M.
    Lenz, O.
    Fevery, B.
    De La Rosa, G.
    Scott, J.
    Sinha, R.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S264 - S265
  • [48] SAFETY AND ANTIVIRAL ACTIVITY OF BI201335, A NEW HCV NS3 PROTEASE INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION GIVEN AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA 2A (P) AND RIBAVIRIN (R)
    Manns, Michael P.
    Bourliere, Marc
    Benhamou, Yves
    Pol, Stanislas
    Bonacini, Maurizio
    Berg, Thomas
    Trepo, Christian
    Wright, David
    Steinmann, Gerhard
    Huang, David B.
    Mikl, Jaromir
    Kukolj, George
    Stern, Jerry O.
    HEPATOLOGY, 2008, 48 (04) : 1133A - 1133A
  • [49] Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks is a safe and effective salvage regimen for NS5A inhibitor-experienced patients with genotype 1-6 hepatitis C virus infection: An integrated analysis of Phase 2 and Phase 3 studies
    Thompson, A.
    Manns, M. P.
    Bourliere, M.
    Stamm, L. M.
    Hyland, R. H.
    Ni, L.
    Dvory-Sobol, H.
    Brainard, D. M.
    Subramanian, G. M.
    Lawitz, E.
    Gane, E. J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 42
  • [50] An Interferon-free, Ribavirin-free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naive Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection
    Everson, Gregory T.
    Sims, Karen D.
    Rodriguez-Torres, Maribel
    Hezode, Christophe
    Lawitz, Eric
    Bourliere, Marc
    Loustaud-Ratti, Veronique
    Rustgi, Vinod K.
    Schwartz, Howard
    Tatum, Harvey A.
    Marcellin, Patrick
    Pol, Stanislas
    Thuluvath, Paul J.
    Eley, Timothy
    Wang, Xiaodong
    Huang, Shu-Pang
    McPhee, Fiona
    Wind-Rotolo, Megan
    Chung, Ellen
    Pasquinelli, Claudio
    Grasela, Dennis M.
    Gardiner, David F.
    HEPATOLOGY, 2012, 56 (06) : 1517 - 1518